#USA #Chicago #Clinical Trials #Kelun-Biotech #oncology research

Kelun-Biotech to Present Key Clinical Findings at 2026 ASCO Annual Meeting in Chicago

The excitement is building for the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be hosted in Chicago from May 29 to June 2. Among the esteemed participants is Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK), which plans to showcase critical results from three influential clinical studies.

Kelun-Biotech stands at the forefront of biopharmaceutical innovation, focusing on developing advanced treatments for serious diseases, particularly solid tumors. The company's flagship product, TROP2 ADC sacituzumab tirumotecan (sac-TMT), next-generation RET inhibitor lunbotinib fumarate (A400/EP0031), and the new ADC SKB500 will be highlighted at the event.

Clinical Trial Highlights

The abstracts detailing these studies are set to be published on the ASCO website on May 21, 2026. Here’s what attendees can expect from the presentations:

1. Sacituzumab Tirumotecan (Sac-TMT) plus Pembrolizumab for NSCLC
This randomized, controlled phase III study (OptiTROP-Lung05) pitted sac-TMT alongside pembrolizumab against pembrolizumab alone as first-line treatment for PD-L1-positive advanced non-small cell lung cancer (NSCLC). - Abstract Number: 8506
- Presentation Date: May 29, 3:12 PM - 3:24 PM CDT

2. Lunbotinib (A400/EP0031) Safety and Efficacy
Featured will be findings from a pivotal phase II study assessing lunbotinib, a selective RET inhibitor, in patients with advanced RET fusion-positive NSCLC. - Abstract Number: 8505
- Presentation Date: May 29, 2:36 PM - 2:48 PM CDT

3. SKB500 First-in-Human Study
Kelun-Biotech will also report on SKB500, a novel ADC in patients with locally advanced or metastatic solid tumors during an open-label study. - Abstract Number: 3011
- Presentation Date: June 2, 9:57 AM - 10:03 AM CDT

About Sac-TMT

Sac-TMT is heralded as a groundbreaking ADC targeting advanced solid tumors such as NSCLC, breast cancer, gastric cancer, and others. Its innovative technology employs a unique bifunctional linker maximizing payload delivery directly to tumor cells. The drug has witnessed considerable approval success, currently having four indications in the Chinese market, including two for unresectable or metastatic triple-negative breast cancer (TNBC) and non-squamous NSCLC after other treatments have failed. The promising statistics indicate the substantial benefits it can bring to patients across various indications, enhanced by its inclusion in China's National Reimbursement Drug List.

Moreover, this drug holds the distinction of being the world's first TROP2 ADC approved for lung cancer treatment, bolstering Kelun-Biotech's reputation and market position in the competitive landscape of oncology therapeutics.

About Lunbotinib and SKB500

Lunbotinib, targeted primarily for NSCLC and medullary thyroid cancer, is under scrutiny as the Center for Drug Evaluation reviews its NDA in China. Furthermore, SKB500, developed with Kelun's proprietary OptiDC™ platform, has shown promising efficacy in preclinical studies for a range of solid tumors and is currently being evaluated in correlation with immunotherapy for advanced small cell lung cancer.

Kelun-Biotech's Commitment to Innovation

Kelun-Biotech, a subsidiary of Kelun Pharmaceutical, is deeply committed to addressing unmet medical needs globally with an extensive pipeline of innovative drug projects – currently over 30, including four already on the market. The ambition is to lead on an international scale in developing biological and small molecule drugs, aiming for both domestic and global impacts in the fight against serious diseases like cancer.

As the ASCO meeting approaches, the anticipation grows not just for Kelun-Biotech's presentations but for the broader implications these findings may hold for the future of oncology treatment. The company is setting the stage for discussions on the evolving landscape of cancer therapeutics, where innovation meets patient care.